215 results on '"Peter Tan"'
Search Results
52. WHY INNOVATE IN MARKETING? A CASE OF POSH NAIL SPA
- Author
-
Ng Yin Kuan, Lai Ka Fei, Fong Chee Yang, Kuek Thiam Yong, Lim Yoong Hing, Peter Tan Sin Howe, and Nurliyana Maludin
- Abstract
Manicures and pedicures are gaining market popularity in Malaysia. The evolution in beauty and personal care industry offers more opportunity for small businesses in marketing personal care and cosmetics products. There is an increasing number of nail salons providing manicures and pedicures services as well as nail art in the city; mostly in middle to high-end shopping malls, business centres or standalone nail salon in commercial shop lots. The consumers are mostly influenced by heavy advertising, for instance advent of K-pop and K-drama, marketing activities and growing trends of chasing beauty. The beauty industry or more specifically the nail care segment is highly fragmented due to various customers with different needs and wants pertaining to service levels, product categories and pricing. Hence, innovative marketing will become an important tool to success. The conventional marketing strategies are no longer effective as the businesses are propelled by the advancement of technology and change in social factors. The departure of conventional marketing strategies is necessary for the vendor to open new market segment and to increase sales. This study will explore the innovative marketing strategies in nail salon through case study method. The study also aims to discover on how the vendor overcome the challenges faced in this industry. The discussion will review the new approaches used as a new marketing idea brought in by the business.
- Published
- 2019
- Full Text
- View/download PDF
53. Counterpossible Non-vacuity in Scientific Practice
- Author
-
Peter Tan
- Subjects
Philosophy ,Contemporary philosophy ,Analytic philosophy ,Scientific practice ,Epistemology - Published
- 2019
- Full Text
- View/download PDF
54. End-of-Life Care Among Patients With Kidney Failure on Maintenance Dialysis: A Retrospective Population-Based Study
- Author
-
Shuaib Hafid, Sarina R. Isenberg, Aleisha Fernandes, Erin Gallagher, Colleen Webber, Meera Joseph, Manish M Sood, Adrianna Bruni, Janet L. Davis, Grace Warmels, James Downar, Anastasia Gayowsky, Aaron Jones, Doug Manuel, Peter Tanuseputro, and Michelle Howard
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Background: Nephrologists routinely provide end-of-life care for patients with kidney failure (KF) on maintenance dialysis. Involvement of primary care and palliative care physicians may enhance this experience. Objective: The objective was to describe outpatient care patterns in the last year of life and the end-of-life acute care utilization for patients with KF on maintenance dialysis. Design: Retrospective cohort study using population-level health administrative data. Setting & Participants: Outpatient and inpatient care during the last year of life among patients who died between 2017 and 2019, receiving maintenance dialysis in Ontario, Canada. Measurements: The primary exposure is patterns of physician specialties providing outpatient care in the last year of life. Outcomes include outpatient encounters in the last year of life, acute care visitation in the last month of life, and place of death. Methods: We reported the count and percentage of categorical outcomes and the median (interquartile range) for numeric outcomes. We produced time series plots of the mean monthly percentage of encounters to different specialties stratified by physician specialty patterns. We evaluated differences in outcomes by physician specialty patterns using analysis of variance (ANOVA) and Pearson’s chi-square tests ( P < .05, two-tailed). Results: Among 6866 patients, the median age at death was 73, 36.1% were female, and 87.8% resided in urban regions. Three patterns emerged: a primary care, nephrology, and palliative care triad (25.5%); a primary care and nephrology dyad (59.3%); and a non-primary care pattern (15.2%). Palliative care involvement is concentrated near death. Of all, 81.4% spent at least 1 day in hospital or emergency department in the last month, but those with primary care, palliative care, and nephrology involvement had the fewest acute care deaths (65.8%). Limitations: Outpatient care patterns were defined using physician billing codes, potentially missing care from other providers. Conclusions: Nephrology and primary care predominantly manage outpatient care in the last year of life for patients with KF on maintenance dialysis, with consistent acute care use across care patterns except for the place of death. Future research should explore associations between patterns of care and end-of-life outcomes to identify the most optimal model of care for patients with KF on maintenance dialysis.
- Published
- 2024
- Full Text
- View/download PDF
55. Barriers to Discharge of Hip Fracture Patients From An Academic Hospital: A Retrospective Data Analysis
- Author
-
Chantal Backman RN, MHA, PhD, Franciely D. Engel PhD, Colleen Webber PhD, Anne Harley CCFP, COE, FCFP, Peter Tanuseputro MD, Ana Lúcia Schaefer Ferreira de Mello PhD, Gabriela Marcellino de Melo Lanzoni PhD, and Steve Papp MD, MSc, FRCSC
- Subjects
Orthopedic surgery ,RD701-811 ,Geriatrics ,RC952-954.6 - Abstract
Introduction Adherence to best practices for care of hip fracture patients is fundamental to decreasing morbidity and mortality in older adults. This includes timely transfer from the hospital to rehabilitation soon after their surgical care. Hospitals experience challenges in implementing several best practices. We examined the potential barriers associated with timely discharge for patients who underwent a hip fracture surgery in an academic hospital in Ontario, Canada. Methods We conducted a retrospective cross-sectional review of a local database. We used descriptive statistics to characterize individuals according to the time of discharge after surgery. Multivariable binary logistic regression was used to evaluate factors associated with delayed discharge (>6 days post-surgery). Results A total of 492 patients who underwent hip fracture surgery between September 2019 and August 2020 were included in the study. The odds of having a delayed discharge occurred when patients had a higher frailty score (odds ratios [OR] 1.19, 95% confidence interval [CI] 1.02;1.38), experienced an episode of delirium (OR 2.54, 95% CI 1.35;4.79), or were non-weightbearing (OR 3.00, 95% CI 1.07;8.43). Patients were less likely to have a delayed discharge when the surgery was on a weekend (OR .50, 95% CI .32;.79) compared to a weekday, patients had a total hip replacement (OR .28, 95% CI .10;.80) or dynamic hip screw fixation (OR .49, 95% CI .25;.98) compared to intramedullary nails, or patients who were discharged to long-term care (OR .05, 95% CI .02;.13), home (OR .26, 95% CI .15;.46), or transferred to another specialty in the hospital (OR .49, 95% CI .29;.84) compared to inpatient rehabilitation. Conclusions Clinical and organizational factors can operate as potential barriers to timely discharge after hip fracture surgery. Further research is needed to understand how to overcome these barriers and implement strategies to improve best practice for post-surgery hip fracture care.
- Published
- 2024
- Full Text
- View/download PDF
56. What are the views of Quebec and Ontario citizens on the tiebreaker criteria for prioritizing access to adult critical care in the extreme context of a COVID-19 pandemic?
- Author
-
Claudia Calderon Ramirez, Yanick Farmer, Andrea Frolic, Gina Bravo, Nathalie Orr Gaucher, Antoine Payot, Lucie Opatrny, Diane Poirier, Joseph Dahine, Audrey L’Espérance, James Downar, Peter Tanuseputro, Louis-Martin Rousseau, Vincent Dumez, Annie Descôteaux, Clara Dallaire, Karell Laporte, and Marie-Eve Bouthillier
- Subjects
COVID-19 prioritization ,Tiebreakers ,Critical care ,Democratic deliberation ,Clinical ethics ,Medical philosophy. Medical ethics ,R723-726 - Abstract
Abstract Background The prioritization protocols for accessing adult critical care in the extreme pandemic context contain tiebreaker criteria to facilitate decision-making in the allocation of resources between patients with a similar survival prognosis. Besides being controversial, little is known about the public acceptability of these tiebreakers. In order to better understand the public opinion, Quebec and Ontario’s protocols were presented to the public in a democratic deliberation during the summer of 2022. Objectives (1) To explore the perspectives of Quebec and Ontario citizens regarding tiebreakers, identifying the most acceptable ones and their underlying values. (2) To analyze these results considering other public consultations held during the pandemic on these criteria. Methods This was an exploratory qualitative study. The design involved an online democratic deliberation that took place over two days, simultaneously in Quebec and Ontario. Public participants were selected from a community sample which excluded healthcare workers. Participants were first presented the essential components of prioritization protocols and their related issues (training session day 1). They subsequently deliberated on the acceptability of these criteria (deliberation session day 2). The deliberation was then subject to thematic analysis. Results A total of 47 participants from the provinces of Quebec (n = 20) and Ontario (n = 27) took part in the online deliberation. A diverse audience participated excluding members of the healthcare workforce. Four themes were identified: (1) Priority to young patients - the life cycle - a preferred tiebreaker; (2) Randomization - a tiebreaker of last resort; (3) Multiplier effect of most exposed healthcare workers - a median acceptability tiebreaker, and (4) Social value – a less acceptable tiebreaker. Conclusion Life cycle was the preferred tiebreaker as this criterion respects intergenerational equity, which was considered relevant when allocating scarce resources to adult patients in a context of extreme pandemic. Priority to young patients is in line with other consultations conducted around the world. Additional studies are needed to further investigate the public acceptability of tiebreaker criteria.
- Published
- 2024
- Full Text
- View/download PDF
57. Study protocol for the development and validation of a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia
- Author
-
Michael Bonares, Stacey Fisher, Kieran Quinn, Kirsten Wentlandt, and Peter Tanuseputro
- Subjects
Dementia ,Hospitals ,Prognosis ,Mortality ,Advance care planning ,Palliative care ,Medicine (General) ,R5-920 - Abstract
Abstract Background Patients with dementia and their caregivers could benefit from advance care planning though may not be having these discussions in a timely manner or at all. A prognostic tool could serve as a prompt to healthcare providers to initiate advance care planning among patients and their caregivers, which could increase the receipt of care that is concordant with their goals. Existing prognostic tools have limitations. We seek to develop and validate a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia. Methods The derivation cohort will include approximately 235,000 patients with dementia, who were admitted to hospital in Ontario from April 1st, 2009, to December 31st, 2017. Predictor variables will be fully prespecified based on a literature review of etiological studies and existing prognostic tools, and on subject-matter expertise; they will be categorized as follows: sociodemographic factors, comorbidities, previous interventions, functional status, nutritional status, admission information, previous health care utilization. Data-driven selection of predictors will be avoided. Continuous predictors will be modelled as restricted cubic splines. The outcome variable will be mortality within 1 year of admission, which will be modelled as a binary variable, such that a logistic regression model will be estimated. Predictor and outcome variables will be derived from linked population-level healthcare administrative databases. The validation cohort will comprise about 63,000 dementia patients, who were admitted to hospital in Ontario from January 1st, 2018, to March 31st, 2019. Model performance, measured by predictive accuracy, discrimination, and calibration, will be assessed using internal (temporal) validation. Calibration will be evaluated in the total validation cohort and in subgroups of importance to clinicians and policymakers. The final model will be based on the full cohort. Discussion We seek to develop and validate a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia. The model would be integrated into the electronic medical records of hospitals to automatically output 1-year mortality risk upon hospitalization. The tool could serve as a trigger for advance care planning and inform access to specialist palliative care services with prognosis-based eligibility criteria. Before implementation, the tool will require external validation and study of its potential impact on clinical decision-making and patient outcomes. Trial registration NCT05371782.
- Published
- 2024
- Full Text
- View/download PDF
58. Proteomic analysis of decellularized mice liver and kidney extracellular matrices
- Author
-
Anna-Maria Diedrich, Assal Daneshgar, Peter Tang, Oliver Klein, Annika Mohr, Olachi A. Onwuegbuchulam, Sabine von Rueden, Kerstin Menck, Annalen Bleckmann, Mazen A. Juratli, Felix Becker, Igor M. Sauer, Karl H. Hillebrandt, Andreas Pascher, and Benjamin Struecker
- Subjects
Decellularized scaffolds ,Mice liver/kidney matrisome ,Bottom-up proteomics ,Tissue engineering ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background The extracellular matrix (ECM) is a three-dimensional network of proteins that encases and supports cells within a tissue and promotes physiological and pathological cellular differentiation and functionality. Understanding the complex composition of the ECM is essential to decrypt physiological processes as well as pathogenesis. In this context, the method of decellularization is a useful technique to eliminate cellular components from tissues while preserving the majority of the structural and functional integrity of the ECM. Results In this study, we employed a bottom-up proteomic approach to elucidate the intricate network of proteins in the decellularized extracellular matrices of murine liver and kidney tissues. This approach involved the use of a novel, perfusion-based decellularization protocol to generate acellular whole organ scaffolds. Proteomic analysis of decellularized mice liver and kidney ECM scaffolds revealed tissue-specific differences in matrisome composition, while we found a predominantly stable composition of the core matrisome, consisting of collagens, glycoproteins, and proteoglycans. Liver matrisome analysis revealed unique proteins such as collagen type VI alpha-6, fibrillin-2 or biglycan. In the kidney, specific ECM-regulators such as cathepsin z were detected. Conclusion The identification of distinct proteomic signatures provides insights into how different matrisome compositions might influence the biological properties of distinct tissues. This experimental workflow will help to further elucidate the proteomic landscape of decellularized extracellular matrix scaffolds of mice in order to decipher complex cell–matrix interactions and their contribution to a tissue-specific microenvironment.
- Published
- 2024
- Full Text
- View/download PDF
59. Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes
- Author
-
Andrew Baird, Abdullah Nasser, Peter Tanuseputro, Colleen Webber, Paul Wheatley-Price, and Camille Munro
- Subjects
palliative care ,mesothelioma ,survival ,emergency departments ,patient admission ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Malignant pleural mesothelioma is a rare, aggressive, and incurable cancer with a poor prognosis and high symptom burden. For these patients, little is known about the impact of palliative care consultation on outcomes such as mortality, hospital admissions, or emergency department visits. The aim of this study is to determine if referral to supportive and palliative care in patients with malignant pleural mesothelioma is associated with survival and decreased hospital admissions and emergency department visits. This is a retrospective chart review. Study participants include all malignant pleural mesothelioma patients seen at The Ottawa Hospital—an acute care tertiary center—between January 2002 and March 2019. In total, 223 patients were included in the study. The mean age at diagnosis was 72.4 years and 82.5% were male. Of the patients diagnosed between 2002 and 2010, only 11 (9.6%) were referred to palliative care. By comparison, of those diagnosed between 2011 and 2019, 49 (45.4%) were referred to palliative care. Median time from diagnosis to referral was 4.1 months. There was no significant difference in the median survival of patients referred for palliative care compared to those who did not receive palliative care (p = 0.46). We found no association between receiving palliative care and the mean number of hospital admissions (1.04 vs. 0.91) from diagnosis to death, and an increase in mean number of emergency department visits in the palliative care group (2.30 vs. 1.18). Although there was increased utilization of palliative care services, more than half of the MPM patients did not receive palliative care despite their limited survival. There was an increase in emergency department visits in the palliative care group; this may represent an increase in the symptom burden (i.e., indication bias) in those referred to palliative care.
- Published
- 2024
- Full Text
- View/download PDF
60. Inconsistent idealizations and inferentialism about scientific representation
- Author
-
Peter Tan
- Subjects
History ,History and Philosophy of Science ,Computer science ,media_common.quotation_subject ,Representation (systemics) ,Idealization ,Analogy ,Scientific modelling ,Function (engineering) ,Scientific theory ,Epistemology ,media_common - Abstract
Inferentialists about scientific representation hold that an apparatus's representing a target system consists in the apparatus allowing “surrogative inferences” about the target. I argue that a serious problem for inferentialism arises from the fact that many scientific theories and models contain internal inconsistencies. Inferentialism, left unamended, implies that inconsistent scientific models have unlimited representational power, since an inconsistency permits any conclusion to be inferred. I consider a number of ways that inferentialists can respond to this challenge before suggesting my own solution. I develop an analogy to exploitable glitches in a game. Even though inconsistent representational apparatuses may in some sense allow for contradictions to be generated within them, doing so violates the intended function of the apparatus's parts and hence violates representational “gameplay”.
- Published
- 2020
61. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
- Author
-
Devendra K Hiwase, John Taper, Carly Levetan, Ann Solterbeck, William Roberts, James D'Rozario, Anthony Richard Powell, Robert Traficante, Luke R. Anderson, Timothy P. Hughes, Ian Irving, Peter Tan, David T Yeung, Susan Branford, Othon L Gervasio, Matthew Wright, Hiwase, Devendra, Tan, Peter, D'Rozario, James, Taper, John, Powell, Anthony, Irving, Ian, Wright, Matthew, Branford, Susan, Yeung, David T, Anderson, Luke, Gervasio, Othon, Levetan, Carly, Roberts, Will, Solterbeck, Ann, Traficante, Robert, and Hughes, Timothy
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Dasatinib ,Tyrosine kinase inhibitor ,Antineoplastic Agents ,Drug Administration Schedule ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Adverse effect ,Protein Kinase Inhibitors ,neoplasms ,Aged ,business.industry ,Chronic myeloid leukemia ,Myeloid leukemia ,Imatinib ,Hematology ,Middle Aged ,Protein-Tyrosine Kinases ,Nilotinib ,Pyrimidines ,Treatment Outcome ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Female ,business ,Tyrosine kinase ,030215 immunology ,medicine.drug - Abstract
usc Background: Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic phase chronic myeloid leukemia (CML-CP) experience intolerable adverse events. Management strategies in-clude dose adjustments, interrupting or discontinuing therapy, or switching to an alternative TKI. Methods: This multicenter, single-arm, Phase IIIb study included CML-CP patients intolerant of, but responsive to, first-line treatment with imatinib or dasatinib. All patients were switched to nilotinib 300 mg bid for up to 24 months. The primary endpoint was achievement of MR4.5 (BCR-ABL transcript level of ≤ 0.0032% on the International Scale) by 24 months. Results: Twenty patients were enrolled in the study (16 imatinib-intolerant, 4 dasatinib-intolerant); which was halted early because of low recruitment. After the switch to nilotinib 300 mg bid, MR4.5 at any time point up to month 24 was achieved in 10 of 20 patients (50%) in the full analysis set. Of the non-hematological adverse events associated with intolerance to prior imatinib or dasatinib, 74% resolved within 12 weeks of switching tonilotinib 300 mg bid. Conclusion: Nilotinib 300 mg bid shows minimal cross intolerance in patients with CML-CP who have prior toxicities to other TKIs and can lead to deep molecular responses. Refereed/Peer-reviewed
- Published
- 2018
- Full Text
- View/download PDF
62. Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation
- Author
-
Melita Cirillo, Peter Tan, Marian Sturm, and Catherine Cole
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Mesenchymal Stem Cell Transplantation ,Cancer Vaccines ,Immunotherapy, Adoptive ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Internal medicine ,medicine ,Animals ,Humans ,Bone Marrow Transplantation ,Transplantation ,Hematology ,business.industry ,Dendritic Cells ,Dendritic cell ,Immunotherapy ,medicine.disease ,Leukemia ,030104 developmental biology ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Immunology ,Cancer research ,Stem cell ,business - Abstract
Immunotherapy has changed treatment practices for many hematologic malignancies. Even in the current era of targeted therapy, chemotherapy remains the backbone of treatment for many hematologic malignancies, especially in acute leukemias, where relapse remains the major cause of mortality. Application of novel immunotherapies in hematology attempts to harness the killing power of the immune system against leukemia and lymphoma. Cellular immunotherapy is evolving rapidly for high-risk hematologic disorders. Recent advances include chimeric antigen-receptor T cells, mesenchymal stromal/stem cells, dendritic cell tumor vaccines, cytokine-induced killer cells, and virus-specific T cells. The advantages of nontransplantation cellular immunotherapy include suitability for patients for whom transplantation has failed or is contraindicated, and a potentially less-toxic treatment alternative to transplantation for relapsed/refractory patients. This review examines those emerging cellular immunotherapies that are changing treatment paradigms for patients with hematologic malignancies.
- Published
- 2018
- Full Text
- View/download PDF
63. COVID-19 vaccine uptake among Ontario physicians: a descriptive population-based retrospective cohort study
- Author
-
Manish M Sood, Amit X Garg, Peter Tanuseputro, Eric McArthur, Jessica M Sontrop, Kevin L Schwartz, Daniel T Myran, Cheng-Wei Liu, and Nivethika Jeyakumar
- Subjects
Medicine - Abstract
Objectives To determine COVID-19 vaccine uptake among physicians in Ontario, Canada from 14 December 2020 to 13 February 2022.Design Population-based retrospective cohort study.Setting All registered physicians in Ontario, Canada using data from linked provincial administrative healthcare databases.Participants 41 267 physicians (including postgraduate trainees) who were Ontario residents and registered with the College of Physicians and Surgeons of Ontario were included. Physicians who were out of province, had not accessed Ontario Health Insurance Plan-insured services for their own care for ≥5 years and those with missing identifiers were excluded.Primary and secondary outcome measures Primary outcomes were the proportions of physicians who were recorded to have received at least one, at least two and three doses of a Health Canada-approved COVID-19 vaccine by study end date. Secondary outcomes were how uptake varied by physician characteristics (including age, sex, specialty and residential location) and time elapsed between doses.Results Of 41 267 physicians, (56% male, mean age 47 years), 39 359 (95.4%) received at least one dose, 39 148 (94.9%) received at least two doses and 35 834 (86.8%) received three doses of a COVID-19 vaccine. Of those who received three doses, the proportions were 90.4% among those aged ≥60 years and 81.2–89.5% among other age groups; 88.7% among family physicians and 89% among specialists. 1908 physicians (4.6%) had no record of vaccination, and this included 3.4% of family physicians and 4.1% of specialists; however, 28% of this group had missing specialty information.Conclusions In Ontario, within 14 months of COVID-19 vaccine availability, 86.8% of physicians had three doses of a COVID-19 vaccine, compared with 45.6% of the general population. Findings may signify physicians’ confidence in the safety and effectiveness of COVID-19 vaccines.
- Published
- 2024
- Full Text
- View/download PDF
64. Depletion of donor dendritic cells ameliorates immunogenicity of both skin and hind limb transplants
- Author
-
Muhammad Imtiaz Ashraf, Joerg Mengwasser, Anja Reutzel-Selke, Dietrich Polenz, Kirsten Führer, Steffen Lippert, Peter Tang, Edward Michaelis, Rusan Catar, Johann Pratschke, Christian Witzel, Igor M. Sauer, Stefan G. Tullius, and Barbara Kern
- Subjects
acute cellular rejection ,vascularized composite-tissue allografts (VCA) ,antigen presenting cells (APCs) ,conventional dendritic cells (cDCs) ,allograft immunogenicity ,mouse models of skin and hind limb transplantation ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Acute cellular rejection remains a significant obstacle affecting successful outcomes of organ transplantation including vascularized composite tissue allografts (VCA). Donor antigen presenting cells (APCs), particularly dendritic cells (DCs), orchestrate early alloimmune responses by activating recipient effector T cells. Employing a targeted approach, we investigated the impact of donor-derived conventional DCs (cDCs) and APCs on the immunogenicity of skin and skin-containing VCA grafts, using mouse models of skin and hind limb transplantation. By post-transplantation day 6, skin grafts demonstrated severe rejections, characterized by predominance of recipient CD4 T cells. In contrast, hind limb grafts showed moderate rejection, primarily infiltrated by CD8 T cells. Notably, the skin component exhibited heightened immunogenicity when compared to the entire VCA, evidenced by increased frequencies of pan (CD11b-CD11c+), mature (CD11b-CD11c+MHCII+) and active (CD11b-CD11c+CD40+) DCs and cDC2 subset (CD11b+CD11c+ MHCII+) in the lymphoid tissues and the blood of skin transplant recipients. While donor depletion of cDC and APC reduced frequencies, maturation and activation of DCs in all analyzed tissues of skin transplant recipients, reduction in DC activities was only observed in the spleen of hind limb recipients. Donor cDC and APC depletion did not impact all lymphocyte compartments but significantly affected CD8 T cells and activated CD4 T in lymph nodes of skin recipients. Moreover, both donor APC and cDC depletion attenuated the Th17 immune response, evident by significantly reduced Th17 (CD4+IL-17+) cells in the spleen of skin recipients and reduced levels of IL-17E and lymphotoxin-α in the serum samples of both skin and hind limb recipients. In conclusion, our findings underscore the highly immunogenic nature of skin component in VCA. The depletion of donor APCs and cDCs mitigates the immunogenicity of skin grafts while exerting minimal impact on VCA.
- Published
- 2024
- Full Text
- View/download PDF
65. The association between physical availability of cannabis retail outlets and frequent cannabis use and related health harms: a systematic review
- Author
-
Nathan Cantor, Max Silverman, Adrienne Gaudreault, Brian Hutton, Catherine Brown, Tara Elton-Marshall, Sameer Imtiaz, Lindsey Sikora, Peter Tanuseputro, and Daniel T. Myran
- Subjects
Cannabis ,Non-medical cannabis legalisation ,Commercialization ,Retail access ,Recreational cannabis legalisation ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: An increasing number of regions have or are considering legalising the sale of cannabis for adult use. Experience from tobacco and alcohol regulation has found that greater access to physical retail stores is positively associated with increased substance use and harm. Whether this association exists for cannabis is unclear. We completed a systematic review examining the association between cannabis retail store access and adverse health outcomes. We identified articles up until July 20, 2023 by searching four databases. We included studies examining the association between measures of cannabis store access and adverse outcomes: frequent or problematic cannabis use, healthcare encounters due to cannabis use (e.g., cannabis-induced psychosis), and healthcare encounters potentially related to cannabis (e.g., self-harm episodes). Results were compared by study design type, retail access measure, and by subgroups including: children, adolescents, young adults, adults, and pregnant individuals. This review was registered with PROSPERO (CRD42021281788). The search generated 5750 citations of which we included 32 studies containing 44 unique primary analyses (unique retail measure and outcome pairs). Studies come from 4 countries (United States, Canada, Netherlands and Uruguay). Among the included analyses, there were consistent positive associations between greater cannabis retail access and 1) increased healthcare service use or poison control calls directly due to cannabis (10/12 analyses; 83%) (2) increased cannabis use and cannabis-related hospitalization during pregnancy (4/4; 100%) and 3) frequent cannabis use in adults and young adults (7/11; 64%). There was no consistent positive association between greater cannabis retail and increased frequent cannabis use in adolescents (1/4; 25%), healthcare service use potentially related to cannabis (2/6; 33%) or increased adverse neonatal birth outcomes (2/7; 26.8%). There is a positive association between greater cannabis store access and increases in cannabis harm. In countries with legal cannabis, retail restrictions may reduce use and harm. Funding: Canadian Centre on Substance Use and Addiction (CCSA).
- Published
- 2024
- Full Text
- View/download PDF
66. Prevalence and patterns of multimorbidity among linguistic groups of patients receiving home care in Ontario: a retrospective cohort study
- Author
-
Ricardo Batista, Michael Reaume, Rhiannon Roberts, Emily Seale, Emily Rhodes, Ewa Sucha, Michael Pugliese, Claire E. Kendall, Lise M. Bjerre, Louise Bouchard, Denis Prud’homme, Douglas G. Manuel, and Peter Tanuseputro
- Subjects
Chronic diseases ,Multimorbidity ,Home care ,Linguistic group ,Language barriers ,Elders ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background Prior studies have demonstrated the negative impact of language barriers on access, quality, and safety of healthcare, which can lead to health disparities in linguistic minorities. As the population ages, those with multiple chronic diseases will require increasing levels of home care and long-term services. This study described the levels of multimorbidity among recipients of home care in Ontario, Canada by linguistic group. Methods Population-based retrospective cohort of 510,685 adults receiving home care between April 1, 2010, to March 31, 2018, in Ontario, Canada. We estimated and compared prevalence and characteristics of multimorbidity (2 or more chronic diseases) across linguistic groups (Francophones, Anglophones, Allophones). The most common combinations and clustering of chronic diseases were examined. Logistic regression models were used to explore the main predictors of ‘severe’ multimorbidity (defined as the presence of five or more chronic diseases). Results The proportion of home care recipients with multimorbidity and severe multimorbidity was 92% and 44%, respectively. The prevalence of multimorbidity was slightly higher among Allophones (93.6%) than among Anglophones (91.8%) and Francophones (92.4%). However, Francophones had higher rates of cardiovascular and respiratory disease (64.9%) when compared to Anglophones (60.2%) and Allophones (61.5%), while Anglophones had higher rates of cancer (34.2%) when compared to Francophones (25.2%) and Allophones (24.3%). Relative to Anglophones, Allophones were more likely to have severe multimorbidity (adjusted OR = 1.04, [95% CI: 1.02–1.06]). Conclusions The prevalence of multimorbidity among Ontarians receiving home care services is high; especially for whose primary language is a language other than English or French (i.e., Allophones). Understanding differences in the prevalence and characteristics of multimorbidity across linguistic groups will help tailor healthcare services to the unique needs of patients living in minority linguistic situations.
- Published
- 2023
- Full Text
- View/download PDF
67. Interventions and Counternomic Reasoning
- Author
-
Peter Tan
- Subjects
Philosophy ,History ,History and Philosophy of Science ,060302 philosophy ,05 social sciences ,Psychological intervention ,0501 psychology and cognitive sciences ,06 humanities and the arts ,Sociology ,0603 philosophy, ethics and religion ,050105 experimental psychology ,Epistemology - Abstract
Counternomics—counterfactuals whose antecedents run contrary to the laws of nature—are commonplace in science but have enjoyed relatively little philosophical attention. This article discusses a puzzle about our counternomic epistemology, focusing on cases in which experimental observations are used as evidence for counternomic claims. I show that these cases resist being characterized in familiar interventionist lines, and I suggest a characterization of my own.
- Published
- 2017
- Full Text
- View/download PDF
68. Diagnosis and treatment ofMYH9-RD in an Australasian cohort with thrombocytopenia
- Author
-
Yenna Chun, Lee Ping Chew, Sara Gabrielli, David J. Rabbolini, Maya Latimer, William Stevenson, Peter Tan, Robert Bird, Chris Ward, Benjamin T. Kile, Kottayam Radhakrishnan, Paul Ockelford, Rachel A. Burt, Marie-Christine Morel-Kopp, Kathleen Fixter, Shinji Kunishima, Bhavia Valecha, and Qiang Chen
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Candidate gene ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Splenectomy ,Hematology ,General Medicine ,030204 cardiovascular system & hematology ,Immunofluorescence ,Gastroenterology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Giant platelets ,Internal medicine ,Cohort ,Etiology ,Medicine ,Platelet ,business ,Thrombopoietin - Abstract
MYH9-related disorders (MYH9-RDs) caused by mutation of the MYH9 gene which encodes non-muscle myosin heavy-chain-IIA (NMMHC-IIA), an important motor protein in hemopoietic cells, are the most commonly encountered cause of inherited macrothrombocytopenia. Despite distinguishing features including an autosomal dominant mode of inheritance, giant platelets on the peripheral blood film accompanied by leucocytes with cytoplasmic inclusion bodies (dohle-like bodies), these disorders remain generally under-recognized and often misdiagnosed as immune thrombocytopenia (ITP). This may result in inappropriate treatment with corticosteroids, immunosupressants and in some cases, splenectomy. We explored the efficacy of next generation sequencing (NGS) with a candidate gene panel to establish the aetiology of thrombocytopenia for individuals who had been referred to our center from hematologists in the Australasian region in whom the cause of thrombocytopenia was suspected to be secondary to an inherited condition but which remained uncharacterized despite phenotypic investigations. Pathogenic MYH9 variants were detected in 15 (15/121, 12.4%) individuals and the pathogenecity of a novel variant of uncertain significance was confirmed in a further two related individuals following immunofluorescence (IF) staining performed in our laboratory. Concerningly, only one (1/17) individual diagnosed with MYH9-RD had been referred with this as a presumptive diagnosis, in all other cases (16/17, 94.1%), a diagnosis was not suspected by referring clinicians, indicating a lack of awareness or a failing of our diagnostic approach to these conditions. We examined the mean platelet diameter (MPD) measurements as a means to better identify and quantify platelet size. MPDs in cases with MYH9-RDs were significantly larger than controls (p < 0.001) and in 91% were greater than a previously suggested threshold for platelets in cases of ITP. In addition, we undertook IF staining in a proportion of cases and confirm that this test and/or NGS are satisfactory diagnostic tests. We propose that fewer cases of MYH9-RDs would be missed if diagnostic algorithms prioritized IF and/or NGS in cases of thrombocytopenia associated with giant platelets, even if dohle-like bodies are not appreciated on the peripheral blood film. Finally, our report describes the long-term use of a thrombopoietin agonist in a case of MYH9-RD that had previously been diagnosed as ITP, and demonstrates that treatment with these agents may be possible, and is well tolerated, in this group of patients.
- Published
- 2017
- Full Text
- View/download PDF
69. Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
- Author
-
Robert Kerrin Hills, Julie McManus, Andrew H. Wei, Nik Cummings, Sonali Sadawarte, Peter Tan, Ing Soo Tiong, and John Catalano
- Subjects
0301 basic medicine ,Cancer Research ,Everolimus ,Chemistry ,Low dose cytarabine ,Myeloid leukemia ,Translation (biology) ,Hematology ,mTORC1 ,Discovery and development of mTOR inhibitors ,environment and public health ,enzymes and coenzymes (carbohydrates) ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Phosphorylation ,biological phenomena, cell phenomena, and immunity ,PI3K/AKT/mTOR pathway ,medicine.drug - Abstract
Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) enhances protein translation by deactivating the translation inhibitor 4E-BP1 and phosphorylating p70S6K, which stimulates the initiation of ...
- Published
- 2017
- Full Text
- View/download PDF
70. Post-transitional adaptation of the left heart in uncomplicated, very preterm infants
- Author
-
Peter Tan, Anil Lakkundi, Koert de Waal, and Nilkant Phad
- Subjects
Male ,medicine.medical_specialty ,Contraction (grammar) ,Systole ,Cardiac Volume ,Heart Ventricles ,Gestational Age ,Speckle tracking echocardiography ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Internal medicine ,Ductus arteriosus ,medicine ,Humans ,Fetus ,business.industry ,Infant, Newborn ,Stroke Volume ,General Medicine ,Stroke volume ,Adaptation, Physiological ,Echocardiography, Doppler ,medicine.anatomical_structure ,Blood pressure ,Ventricle ,Infant, Extremely Premature ,Pediatrics, Perinatology and Child Health ,Cardiology ,Gestation ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
BackgroundThe postnatal period in preterm infants involves multiple physiological changes occurring immediately after birth and continuing for days or weeks. To recognise and treat compromise, it is important to measure cardiovascular function. The aim of this study was to describe longitudinal left ventricular function using conventional and novel echocardiography techniques in preterm infants who did not experience significant antenatal or postnatal complications and treatments.MethodsWe prospectively obtained cardiac ultrasound images at days 3, 7, 14, 21, and 28 in 25 uncomplicated, preterm infants ResultsStroke volume increased by 24% during the study period (1.05–1.30 ml/kg, pConclusionStroke volume increased in the first 28 days after preterm birth. The preterm heart adapted by increasing its size, while maintaining systolic and atrial function, independent of early diastolic maturation. Longitudinal deformation of the left ventricle remained unchanged, suggesting relatively preserved function with maturation.
- Published
- 2017
- Full Text
- View/download PDF
71. Identifying predictors of cognitive decline in long-term care: a scoping review
- Author
-
Gaurav Arora, Christina Milani, Peter Tanuseputro, Patrick Tang, Ahwon Jeong, Daniel Kobewka, and Colleen Webber
- Subjects
Long-term care ,Nursing homes ,Assisted-living ,Cognitive decline ,Cognitive impairment ,Cognitive dysfunction ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background Cognitive impairment can cause social, emotional, and financial burdens on individuals, caregivers, and healthcare providers. This is especially important in settings such as long-term care (LTC) homes which largely consist of vulnerable older adults. Thus, the objective of this study is to review and summarize current research examining risk factors of cognitive decline in older adults within LTC. Methods This scoping review includes primary observational research studies assessing within-person change in cognition over time in LTC or equivalent settings in high resource countries. A mean participant age of ≥ 65 years was required. Searches were conducted in Medline, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and PyscInfo on June 27th, 2022 and included articles published during or after the year 2000. Title, abstract, and full-text screening was performed by two independent reviewers using Covidence. Specific predictors along with their associated relation with cognitive decline were extracted by a team of reviewers into a spreadsheet. Results Thirty-eight studies were included in this review. The mean sample size was 14 620. Eighty-seven unique predictors were examined in relation to cognitive decline. Dementia was the most studied predictor (examined by 9 of 38 studies), and the most conclusive, with eight of those studies identifying it as a risk factor for cognitive decline. Other predictors that were identified as risk factors included arterial stiffness (identified by 2 of 2 studies), physical frailty (2 of 2 studies), sub-syndromal delirium (2 of 2 studies), and undergoing the first wave of COVID-19 lockdowns (2 of 2 studies). ADL independence was the most conclusive protective factor (3 of 4 studies), followed by social engagement (2 of 3 studies). Many remaining predictors showed no association and/or conflicting results. Conclusions Dementia was the most common risk factor, while ADL independence was the most common protective factor associated with cognitive decline in LTC residents. This information can be used to stratify residents by risk severity and provide better personalized care for older adults through the targeted management of cognitive decline.
- Published
- 2023
- Full Text
- View/download PDF
72. Intensity of end-of-life care among children with life-threatening conditions: a national population-based observational study
- Author
-
Kimberley Widger, Sarah Brennenstuhl, Katherine E. Nelson, Hsien Seow, Adam Rapoport, Harold Siden, Christina Vadeboncoeur, Sumit Gupta, and Peter Tanuseputro
- Subjects
End-of-life care ,High intensity care ,Life-threatening conditions ,Pediatrics ,RJ1-570 - Abstract
Abstract Background Children with life-threatening conditions frequently experience high intensity care at the end of life, though most of this research only focused on children with cancer. Some research suggests inequities in care provided based on age, disease type, socioeconomic status, and distance that the child lives from a tertiary hospital. We examined: 1) the prevalence of indicators of high intensity end-of-life care (e.g., hospital stays, intensive care unit [ICU] stays, death in ICU, use of cardiopulmonary resuscitation [CPR], use of mechanical ventilation) and 2) the association between demographic and diagnostic factors and each indicator for children with any life-threatening condition in Canada. Methods We conducted a population-based retrospective cohort study using linked health administrative data to examine care provided in the last 14, 30, and 90 days of life to children who died between 3 months and 19 years of age from January 1, 2008 to December 31, 2014 from any underlying life-threatening medical condition. Logistic regression was used to model the association between demographic and diagnostic variables and each indicator of high intensity end-of-life care except number of hospital days where negative binomial regression was used. Results Across 2435 child decedents, the most common diagnoses included neurology (51.1%), oncology (38.0%), and congenital illness (35.9%), with 50.9% of children having diagnoses in three or more categories. In the last 30 days of life, 42.5% (n = 1035) of the children had an ICU stay and 36.1% (n = 880) died in ICU. Children with cancer had lower odds of an ICU stay (OR = 0.47; 95% CI = 0.36–0.62) and ICU death (OR = 0.37; 95%CI = 0.28–0.50) than children with any other diagnoses. Children with 3 or more diagnoses (vs. 1 diagnosis) had higher odds of > 1 hospital stay in the last 30 days of life (OR = 2.08; 95%CI = 1.29–3.35). Living > 400 km (vs
- Published
- 2023
- Full Text
- View/download PDF
73. Association of virtual end-of-life care with healthcare outcomes before and during the COVID-19 pandemic: A population-based study.
- Author
-
John M Lapp, Thérèse A Stukel, Hannah Chung, Chaim M Bell, R Sacha Bhatia, Allan S Detsky, James Downar, Sarina R Isenberg, Douglas S Lee, Nathan Stall, Peter Tanuseputro, and Kieran L Quinn
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
The use of virtual care for people at the end-of-life significantly increased during the COVID-19 pandemic, but its association with acute healthcare use and location of death is unknown. The objective of this study was to measure the association between the use of virtual end-of-life care with acute healthcare use and an out-of-hospital death before vs. after the introduction of specialized fee codes that enabled broader delivery of virtual care during the COVID-19 pandemic. This was a population-based cohort study of 323,995 adults in their last 90 days of life between January 25, 2018 and December 31, 2021 using health administrative data in Ontario, Canada. Primary outcomes were acute healthcare use (emergency department, hospitalization) and location of death (in or out-of-hospital). Prior to March 14, 2020, 13,974 (8%) people received at least 1 virtual end-of-life care visit, which was associated with a 16% higher rate of emergency department use (adjusted Rate Ratio [aRR] 1.16, 95%CI 1.12 to 1.20), a 17% higher rate of hospitalization (aRR 1.17, 95%CI 1.15 to 1.20), and a 34% higher risk of an out-of-hospital death (aRR 1.34, 95%CI 1.31 to 1.37) compared to people who did not receive virtual end-of-life care. After March 14, 2020, 104,165 (71%) people received at least 1 virtual end-of-life care visit, which was associated with a 58% higher rate of an emergency department visit (aRR 1.58, 95%CI 1.54 to 1.62), a 45% higher rate of hospitalization (aRR 1.45, 95%CI 1.42 to 1.47), and a 65% higher risk of an out-of-hospital death (aRR 1.65, 95%CI 1.61 to 1.69) compared to people who did not receive virtual end-of-life care. The use of virtual end-of-life care was associated with higher acute healthcare use in the last 90 days of life and a higher likelihood of dying out-of-hospital, and these rates increased during the pandemic.
- Published
- 2024
- Full Text
- View/download PDF
74. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
- Author
-
John Catalano, Anthony P. Schwarer, Shaun Fleming, Giovanna Pomilio, Peter Tan, Sushrut Patil, Julie McManus, Ing Soo Tiong, Mark Droogleever, Andrew H. Wei, Sharon Avery, Andrew Spencer, and Nik Cummings
- Subjects
0301 basic medicine ,Oncology ,azacitidine ,medicine.medical_specialty ,Azacitidine ,acute myeloid leukemia ,Neutropenia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Mucositis ,Everolimus ,Hematology ,business.industry ,Myeloid leukemia ,clinical trial ,everolimus ,medicine.disease ,Surgery ,Transplantation ,030104 developmental biology ,030220 oncology & carcinogenesis ,mTOR ,business ,Febrile neutropenia ,Research Paper ,medicine.drug - Abstract
// Peter Tan 1 , Ing Soo Tiong 1, 2 , Shaun Fleming 1 , Giovanna Pomilio 2 , Nik Cummings 3 , Mark Droogleever 4 , Julie McManus 3 , Anthony Schwarer 5 , John Catalano 6 , Sushrut Patil 1 , Sharon Avery 1 , Andrew Spencer 1, 2 and Andrew Wei 1, 2 1 Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia 2 Australian Centre for Blood Diseases, Monash University, Melbourne, Australia 3 Department of Pathology, Alfred Hospital, Melbourne, Australia 4 Faculty of Medicine, University of Amsterdam, Amsterdam, The Netherlands 5 Eastern Health Clinical School, Monash University, Box Hill, Australia 6 Clinical Haematology, Frankston Hospital, Frankston, Australia Correspondence to: Andrew Wei, email: andrew.wei@monash.edu Keywords: acute myeloid leukemia, everolimus, azacitidine, mTOR, clinical trial Received: October 21, 2016 Accepted: November 20, 2016 Published: November 29, 2016 ABSTRACT Therapeutic options are limited in relapsed/refractory acute myeloid leukemia (AML). We evaluated the maximum tolerated dose (MTD) and preliminary efficacy of mammalian target of rapamycin (mTOR) inhibitor, everolimus (days 5–21) in combination with azacitidine 75 mg/m 2 subcutaneously (days 1–5 and 8–9 every 28 days) in 40 patients with relapsed ( n = 27), primary refractory ( n = 11) or elderly patients unfit for intensive chemotherapy ( n = 2). MTD was not reached following everolimus dose escalation (2.5, 5 or 10 mg; n = 19) to the 10 mg dose level which was expanded ( n = 21). Major adverse events (grade > 2) were mostly disease-related: neutropenia (73%), thrombocytopenia (67%), mucositis (24%) and febrile neutropenia (19%). Overall survival (OS) of the entire cohort was 8.5 months, and overall response rate (ORR; including CR/CRi/PR/MLFS) was 22.5%. Furthermore, a landmark analysis beyond cycle 1 revealed superior OS and ORR in patients receiving 2.5 mg everolimus with azoles, compared to those without azoles (median OS 12.8 vs. 6.0 months, P = 0.049, and ORR 50% vs. 16%, P = 0.056), potentially due to achievement of higher everolimus blood levels. This study demonstrates that everolimus in combination with azacitidine is tolerable, with promising clinical activity in advanced AML.
- Published
- 2016
- Full Text
- View/download PDF
75. Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
- Author
-
Denice Hickman, Jing Gong, Stephanie M. Kapsalis, Peter Tan, Du Lam, Hartmut Döhner, Thomas Winkler, Emmanuel Raffoux, Courtney D. DiNardo, Stéphane de Botton, Scott R. Daigle, Richard Stone, Xiwei Wang, Amir T. Fathi, Giovanni Martinelli, Paresh Vyas, Hagop M. Kantarjian, Olga Frankfurt, Vickie Zhang, Andre C. Schuh, Anthony S. Stein, Amer M. Zeidan, and Eytan M. Stein
- Subjects
Cancer Research ,IDH1 ,Oncology ,business.industry ,Azacitidine ,Mutant ,Cancer research ,medicine ,Myeloid leukemia ,Hematology ,Newly diagnosed ,business ,medicine.drug - Published
- 2019
- Full Text
- View/download PDF
76. PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
- Author
-
Hartmut Döhner, Andre C. Schuh, Prapti A. Patel, Giovanni Martinelli, Jing Gong, Stephanie M. Kapsalis, Amir T. Fathi, Courtney Dinardo, S. de Botton, Du Hung Lam, Vickie Zhang, Anthony S. Stein, Richard Stone, Olga Frankfurt, Xuemei Wang, Amer M. Zeidan, Eytan M. Stein, Hagop M. Kantarjian, Thomas Winkler, Peter Tan, Denice Hickman, Bin Wu, Emmanuel Raffoux, and Paresh Vyas
- Subjects
IDH1 ,business.industry ,Mutant ,Azacitidine ,Cancer research ,Medicine ,Myeloid leukemia ,Hematology ,Newly diagnosed ,business ,medicine.drug - Published
- 2019
- Full Text
- View/download PDF
77. WHY INNOVATE IN MARKETING? A CASE OF POSH NAIL SPA
- Author
-
Kuan, Ng Yin, primary, Fei, Lai Ka, additional, Yang, Fong Chee, additional, Yong, Kuek Thiam, additional, Hing, Lim Yoong, additional, Howe, Peter Tan Sin, additional, and Maludin, Nurliyana, additional
- Published
- 2019
- Full Text
- View/download PDF
78. Cardiac Function After the Immediate Transitional Period in Very Preterm Infants Using Speckle Tracking Analysis
- Author
-
Peter Tan, Koert de Waal, Nilkant Phad, and Anil Lakkundi
- Subjects
Cardiac function curve ,Cardiac output ,medicine.medical_specialty ,Diastole ,Gestational Age ,Speckle tracking echocardiography ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Internal medicine ,Ductus arteriosus ,Humans ,Medicine ,Enlarged heart ,Ductus Arteriosus, Patent ,business.industry ,Australia ,Infant, Newborn ,Reproducibility of Results ,Heart ,Stroke Volume ,Stroke volume ,medicine.disease ,Preload ,medicine.anatomical_structure ,Echocardiography ,Infant, Extremely Premature ,Pediatrics, Perinatology and Child Health ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
The postnatal period in preterm infants involves multiple physiologic changes starting directly after birth and continuing for days or weeks. To recognize and treat compromise, it is important to measure cardiovascular function. We used a novel technique (speckle tracking echocardiography, STE) to measure cardiac function in this period. We obtained cardiac ultrasound images at day 3, 7, 14, 21 and 28 in preterm infants
- Published
- 2015
- Full Text
- View/download PDF
79. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
- Author
-
Sushrut Patil, Julie McManus, Magdalena Plebanski, Peter Tan, Sarah Nicole Perruzza, William C Stevenson, Andrew H. Wei, Sharon Avery, Andrew Spencer, Shaun Fleming, and Chindu Govindaraj
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,NPM1 ,medicine.medical_treatment ,Azacitidine ,Pharmacology ,DNA Methyltransferase 3A ,Maintenance Chemotherapy ,Maintenance therapy ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,DNA (Cytosine-5-)-Methyltransferases ,Lenalidomide ,Aged ,Chemotherapy ,business.industry ,Hematology ,Middle Aged ,Thalidomide ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Tolerability ,Concomitant ,Mutation ,Toxicity ,Female ,business ,Nucleophosmin ,medicine.drug - Abstract
In this Phase 1b study, the safety and tolerability of maintenance therapy, comprising lenalidomide (0-25 mg, days 5-25) in combination with azacitidine (50-75 mg/m(2) , days 1-5) every 28 d, was explored in 40 patients with acute myeloid leukaemia (AML) in complete remission after chemotherapy. Eligibility included AML in first complete remission (CR1) with adverse risk karyotype (n = 8), fms-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) (n = 5), age ≥60 years (n = 31) or AML in second remission (CR2) (n = 14). Dose-limiting toxicity was not reached. Common toxicities were haematological, infection, injection pain, constipation, fatigue and diarrhoea. In CR1, median relapse-free (RFS) and overall survival (OS) was 12 and 20 months, respectively. In CR2, median RFS was 11 months, with median OS not yet reached. Among 29 patients with intermediate cytogenetic risk, RFS was 50% at 24 months. There were five patients with concomitant FLT3-ITD and nucleophosmin (NPM1) mutation; none have relapsed and all are still alive after 17-39 months. Maintenance lenalidomide/azacitidine augmented the function of cytotoxic T lymphocytes, particularly in patients with NPM1 mutation. The lenalidomide/azacitidine maintenance combination was effective in suppressing residual DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A)-positive disease, resulting in sustained remission in patients with concurrent NPM1 mutation. Azacitidine/lenalidomide as maintenance therapy for high-risk AML warrants further exploration.
- Published
- 2015
- Full Text
- View/download PDF
80. Systematic review of validated case definitions to identify hypertensive disorders of pregnancy in administrative healthcare databases
- Author
-
Graeme N Smith, Becky Skidmore, Amy Johnston, Victrine Tseung, Peter Tanuseputro, Thais Coutinho, Jodi D Edwards, and Sonia R Dancey
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Administrative data are frequently used to study cardiovascular disease (CVD) risk in women with hypertensive disorders of pregnancy (HDP). Little is known about the validity of case-finding definitions (CFDs, eg, disease classification codes/algorithms) designed to identify HDP in administrative databases.Methods A systematic review of the literature. We searched MEDLINE, Embase, CINAHL, Web of Science and grey literature sources for eligible studies. Two independent reviewers screened articles for eligibility and extracted data. Quality of reporting was assessed using checklists; risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool, adapted for administrative studies. Findings were summarised descriptively.Results Twenty-six studies were included; most (62%) validated CFDs for a variety of maternal and/or neonatal outcomes. Six studies (24%) reported reference standard definitions for all HDP definitions validated; seven reported all 2×2 table values for ≥1 CFD or they were calculable. Most CFDs (n=83; 58%) identified HDP with high specificity (ie, ≥98%); however, sensitivity varied widely (3%–100%). CFDs validated for any maternal hypertensive disorder had the highest median sensitivity (91%, range: 15%–97%). Quality of reporting was generally poor, and all studies were at unclear or high risk of bias on ≥1 QUADAS-2 domain.Conclusions Even validated CFDs are subject to bias. Researchers should choose the CFD(s) that best align with their research objective, while considering the relative importance of high sensitivity, specificity, negative predictive value and/or positive predictive value, and important characteristics of the validation studies from which they were derived (eg, study prevalence of HDP, spectrum of disease studied, methodological rigour, quality of reporting and risk of bias). Higher quality validation studies on this topic are urgently needed.PROSPERO registration number CRD42021239113.
- Published
- 2023
- Full Text
- View/download PDF
81. Stroke Subtype Among Individuals With Chronic Kidney Disease
- Author
-
Salmi T. Noor, Sarah E. Bota, Anna E. Clarke, William Petrcich, Dearbhla Kelly, Greg Knoll, Gregory L. Hundemer, Mark Canney, Peter Tanuseputro, and Manish M. Sood
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Background: It is widely accepted that there is a stepwise increase in the risk of acute ischemic stroke with chronic kidney disease (CKD). However, whether the risk of specific ischemic stroke subtypes varies with CKD remains unclear. Objective: To assess the association between ischemic stroke subtypes (cardioembolic, arterial, lacunar, and other) classified using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) and CKD stage. Design: retrospective cohort study. Setting: Ontario, Canada. Patients: A total of 17 434 adults with an acute ischemic stroke in Ontario, Canada between April 1, 2002 and March 31, 2013, with an estimated glomerular filtration rate (eGFR) measurement or receipt of maintenance dialysis captured in a stroke registry were included. Measurements: Kidney function categorized as an eGFR of ≥60, 30-59,
- Published
- 2023
- Full Text
- View/download PDF
82. Diagnosis and treatment of
- Author
-
David J, Rabbolini, Yenna, Chun, Maya, Latimer, Shinji, Kunishima, Kathleen, Fixter, Bhavia, Valecha, Peter, Tan, Lee Ping, Chew, Benjamin T, Kile, Rachel, Burt, Kottayam, Radhakrishnan, Robert, Bird, Paul, Ockelford, Sara, Gabrielli, Qiang, Chen, William S, Stevenson, Christopher M, Ward, and Marie-Christine, Morel-Kopp
- Subjects
Adult ,Blood Platelets ,Inclusion Bodies ,Male ,Purpura, Thrombocytopenic, Idiopathic ,Australasia ,Myosin Heavy Chains ,Gene Expression Profiling ,Hearing Loss, Sensorineural ,Recombinant Fusion Proteins ,Gene Expression ,High-Throughput Nucleotide Sequencing ,Receptors, Fc ,Middle Aged ,Thrombocytopenia ,Cohort Studies ,Diagnosis, Differential ,Thrombopoietin ,Mutation ,Humans ,Female ,Mean Platelet Volume ,Cell Size ,Genes, Dominant - Published
- 2017
83. ASEAN-ROK Relations
- Author
-
Peter Tan
- Published
- 2017
- Full Text
- View/download PDF
84. Improving social justice in observational studies: protocol for the development of a global and Indigenous STROBE-equity reporting guideline
- Author
-
Sarah Funnell, Janet Jull, Lawrence Mbuagbaw, Vivian Welch, Omar Dewidar, Xiaoqin Wang, Miranda Lesperance, Elizabeth Ghogomu, Anita Rizvi, Elie A. Akl, Marc T. Avey, Alba Antequera, Zulfiqar A. Bhutta, Catherine Chamberlain, Peter Craig, Luis Gabriel Cuervo, Alassane Dicko, Holly Ellingwood, Cindy Feng, Damian Francis, Regina Greer-Smith, Billie-Jo Hardy, Matire Harwood, Janet Hatcher-Roberts, Tanya Horsley, Clara Juando-Prats, Mwenya Kasonde, Michelle Kennedy, Tamara Kredo, Alison Krentel, Elizabeth Kristjansson, Laurenz Langer, Julian Little, Elizabeth Loder, Olivia Magwood, Michael Johnson Mahande, G. J. Melendez-Torres, Ainsley Moore, Loveline Lum Niba, Stuart G. Nicholls, Miriam Nguilefem Nkangu, Daeria O. Lawson, Ekwaro Obuku, Patrick Okwen, Tomas Pantoja, Jennifer Petkovic, Mark Petticrew, Kevin Pottie, Tamara Rader, Jacqueline Ramke, Alison Riddle, Larissa Shamseer, Melissa Sharp, Bev Shea, Peter Tanuseputro, Peter Tugwell, Janice Tufte, Erik Von Elm, Hugh Sharma Waddington, Harry Wang, Laura Weeks, George Wells, Howard White, Charles Shey Wiysonge, Luke Wolfenden, and Taryn Young
- Subjects
Reporting guidelines ,Health equity ,Social justice ,Observational studies ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Addressing persistent and pervasive health inequities is a global moral imperative, which has been highlighted and magnified by the societal and health impacts of the COVID-19 pandemic. Observational studies can aid our understanding of the impact of health and structural oppression based on the intersection of gender, race, ethnicity, age and other factors, as they frequently collect this data. However, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline, does not provide guidance related to reporting of health equity. The goal of this project is to develop a STROBE-Equity reporting guideline extension. Methods We assembled a diverse team across multiple domains, including gender, age, ethnicity, Indigenous background, disciplines, geographies, lived experience of health inequity and decision-making organizations. Using an inclusive, integrated knowledge translation approach, we will implement a five-phase plan which will include: (1) assessing the reporting of health equity in published observational studies, (2) seeking wide international feedback on items to improve reporting of health equity, (3) establishing consensus amongst knowledge users and researchers, (4) evaluating in partnership with Indigenous contributors the relevance to Indigenous peoples who have globally experienced the oppressive legacy of colonization, and (5) widely disseminating and seeking endorsement from relevant knowledge users. We will seek input from external collaborators using social media, mailing lists and other communication channels. Discussion Achieving global imperatives such as the Sustainable Development Goals (e.g., SDG 10 Reduced inequalities, SDG 3 Good health and wellbeing) requires advancing health equity in research. The implementation of the STROBE-Equity guidelines will enable a better awareness and understanding of health inequities through better reporting. We will broadly disseminate the reporting guideline with tools to enable adoption and use by journal editors, authors, and funding agencies, using diverse strategies tailored to specific audiences.
- Published
- 2023
- Full Text
- View/download PDF
85. A population‐based study of factors associated with systemic treatment in advanced prostate cancer decedents
- Author
-
Jennifer Leigh, Danial Qureshi, Ewa Sucha, Roshanak Mahdavi, Igal Kushnir, Luke T. Lavallée, Dominick Bosse, Colleen Webber, Peter Tanuseputro, and Michael Ong
- Subjects
decedent ,life‐prolonging therapy ,prostate cancer ,regional cancer center ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Introduction Life‐prolonging therapies (LPTs) are rapidly evolving for the treatment of advanced prostate cancer, although factors associated with real‐world uptake are not well characterized. Methods In this cohort of prostate‐cancer decedents, we analyzed factors associated with LPT access. Population‐level databases from Ontario, Canada identified patients 65 years or older with prostate cancer receiving androgen deprivation therapy and who died of prostate cancer between 2013 and 2017. Univariate and multivariable analyses assessed the association between baseline characteristics and receipt of LPT in the 2 years prior to death. Results Of 3575 patients who died of prostate cancer, 40.4% (n = 1443) received LPT, which comprised abiraterone (66.3%), docetaxel (50.3%), enzalutamide (17.2%), radium‐223 (10.0%), and/or cabazitaxel (3.5%). Use of LPT increased by year of death (2013: 22.7%, 2014: 31.8%, 2015: 41.8%, 2016: 49.1%, and 2017: 57.9%, p
- Published
- 2023
- Full Text
- View/download PDF
86. Describing settings of care in the last 100 days of life for cancer decedents: a population‐based descriptive study
- Author
-
Abe Hafid, Michelle Howard, Colleen Webber, Ana Gayowsky, Mary Scott, Aaron Jones, Amy T. Hsu, Peter Tanuseputro, James Downar, Katrin Conen, Doug Manuel, and Sarina R. Isenberg
- Subjects
cancer ,end‐of‐life ,health administrative data ,retrospective studies ,terminal care ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Few studies have described the settings cancer decedents spend their end‐of‐life stage, with none considering homecare specifically. We describe the different settings of care experienced in the last 100 days of life by individuals with cancer and how settings of care change as they approached death. Methods A retrospective cohort study from January 2013 to December 2017, of decedents whose primary cause of death was cancer, using linked population‐level health administrative datasets in Ontario, Canada. Results Decedents 125,755 were included in our cohort. The average age at death was 73, 46% were female, and 14% resided in rural regions. And 24% died of lung cancer, 7% breast, 7% colorectal, 7% pancreatic, 5% prostate, and 50% other cancers. In the last 100 days of life, decedents spent 25.9 days in institutions, 25.8 days receiving care in the community, and 48.3 days at home without any care. Individuals who died of lung and pancreatic cancers spent the most days at home without any care (52.1 and 52.6 days), while individuals who died of prostate and breast cancer spent the least days at home without any care (41.6 and 45.1 days). Regardless of cancer type, decedents spent fewer days at home and more days in institutions as they approached death, despite established patient preferences for an end‐of‐life experience at home. Conclusions In the last 100 days of life, cancer decedents spent most of their time in either institutions or at home without any care. Improving homecare services during the end‐of‐life may provide people dying of cancer with a preferred dying experience.
- Published
- 2023
- Full Text
- View/download PDF
87. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
- Author
-
Guillermo Garcia-Manero, Uma Borate, Katharina Götze, Anne Marie Watson, Ahmed Salem, Jacqueline S. Garcia, Daniel A. Pollyea, Ashish Bajel, William Ainsworth, Fernando Roncolato, Martin Dunbar, John Hayslip, Ying Zhou, Florian Nolte, Olatoyosi Odenike, Andrew M. Brunner, Lori A. Gressick, Ronan Swords, Wan-Jen Hong, Amer M. Zeidan, Jason Harb, and Peter Tan
- Subjects
Oncology ,medicine.medical_specialty ,Venetoclax ,business.industry ,Immunology ,Azacitidine ,Decitabine ,Cell Biology ,Hematology ,Neutropenia ,medicine.disease ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Cytarabine ,Combined Modality Therapy ,Adverse effect ,business ,Febrile neutropenia ,medicine.drug - Abstract
Introduction Over-expression of the anti-apoptotic protein BCL-2 in MDS has been implicated in progression and drug resistance in MDS. Venetoclax (Ven), a selective, potent, orally bioavailable BCL-2 inhibitor, was recently approved in combination with HMAs or low dose cytarabine for the frontline management of older unfit pts with AML. In this study, we sought to evaluate the safety and efficacy of Ven in pts with R/R MDS. Methods This is an ongoing phase 1b, open-label, multicenter study in R/R MDS (NCT02966782). Key eligibility criteria include age ≥18 years, failure of HMA after receiving at least 4 cycles of Aza or 4 cycles of decitabine within the previous 5 years, marrow blasts The primary objectives were to evaluate the safety profiles and the recommended Phase 2 dose (RP2D) of Ven monotherapy and Ven+Aza. Key secondary objectives included a preliminary assessment of overall response rate (ORR, defined as complete remission [CR]+marrow complete remission [mCR]+partial response [PR]) , time to first response (TTR), progression-free survival (PFS), and overall survival (OS). We used the modified International Working Group 2006 criteria for response assessment (Cheson et. al., Blood, 2006). Results As of April 9, 2019, 46 pts [87% male, median age 76 years (range 44-91)] were enrolled. C1 (Ven monotherapy) included 22 pts, C2 (combination therapy) included 24 pts. At baseline, 37 (80%) pts received at least one prior therapy, 2 (15%) pts received 2, and 1 (2%) patient received >3 therapies prior to enrollment in the study. Baseline bone marrow blasts were: ≤5% was observed in 16 (35%) pts, >5% and ≤10% in 23 (50%), and >10% in 7 (15%) pts respectively. Cytogenetics risk was evaluated in 27/46 pts and were as follows: Good 12 (44%), Intermediate 9 (33%), and Poor 6 (22%). Overall, 9 pts discontinued study therapy (8 deaths, 1 withdrew consent). The most frequent treatment-emergent adverse events (TEAEs) included neutropenia, thrombocytopenia, nausea, and diarrhea (Table ). Infectious TEAEs included febrile neutropenia and pneumonia. Predominant Grade 3 and 4 TEAEs were hematological and included neutropenia (41%), thrombocytopenia (30%), leukopenia (24%), and anemia (15%). Serious TEAEs occurring in ≥2 pts were febrile neutropenia (n=8), pneumonia (n=6), thrombocytopenia (n=2), and epistaxis (n=2). Death on study occurred in 8 (17%) pts, of whom 6 died of progressive disease. Other causes of death were septic shock (n=1) and pneumonia (n=1). Forty of 46 pts were response evaluable. Median follow-up time was 4.7 mos (range: 3.7-6.3 mos). In C1, ORR was 7% (1/16). Stable disease was observed in 75% (12/16) pts. Median TTR was 1.6 mos (range: 1.6-1.6 mos). Median PFS was 3.4 mos (95% CI: 1.9-5.2 mos) and 6-mos estimate for OS was 57% (95% CI: 22%, 81%). In C2, ORR was 50% (12/24 pts). Of those, 13% (3/24) had CR and 38% (9/24) had mCR. Stable disease was observed in 31% (10/24) pts. Median PFS, and OS were not reached. The 6-mos estimate for PFS was 76% (95% CI: 50%, 89%) and estimated OS at 9-mos was 83% (95% CI: 55%, 95%). Finally, 4 pts came off study to receive allogeneic stem cell transplantation. Conclusion Ven monotherapy and combination Ven+Aza were well tolerated in pts with R/R MDS and most AEs were manageable. Although the study is still ongoing, the 6-mos OS estimate of 57% in monotherapy pts compares favorably to historical controls. In addition, the ORR observed with combination therapy, and the observed 9-mos OS rate of 83% also compare favorably with historical data. Updated data on safety and efficacy, including data on RP2D, will be presented at the meeting. Disclosures Zeidan: Ariad: Honoraria; Agios: Honoraria; Abbvie: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Otsuka: Consultancy, Honoraria, Research Funding; ADC Therapeutics: Research Funding; Jazz: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Novartis: Honoraria; Astellas: Honoraria; Daiichi Sankyo: Honoraria; Cardinal Health: Honoraria; Seattle Genetics: Honoraria; BeyondSpring: Honoraria; Acceleron Pharma: Consultancy, Honoraria, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Research Funding; Trovagene: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Celgene Corporation: Consultancy, Honoraria, Research Funding; Medimmune/AstraZeneca: Research Funding. Pollyea:Celyad: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Diachii Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Forty-Seven: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees. Garcia:Abbvie: Research Funding; Genentech: Research Funding. Brunner:Novartis: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Research Funding; Forty Seven Inc: Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees. Roncolato:St. George Hospital: Employment. Borate:Novartis: Consultancy; Takeda: Consultancy; Pfizer: Consultancy; Daiichi Sankyo: Consultancy; AbbVie: Consultancy. Odenike:Astra Zeneca: Research Funding; Astex Pharmaceuticals: Research Funding; Agios: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; CTI/Baxalta: Research Funding; NS Pharma: Research Funding; Gilead Sciences: Research Funding; Incyte: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen Oncology: Research Funding; Oncotherapy: Research Funding. Bajel:Amgen: Honoraria, Speakers Bureau; Novartis: Honoraria; AbbVie: Honoraria; Pfizer: Honoraria. Watson:Amgen: Other: Travel grant; Roche: Other: Travel grant. Götze:AbbVie: Membership on an entity's Board of Directors or advisory committees. Nolte:Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Tan:AbbVie Inc: Other: Investigator in AbbVie funded trial. Hong:Roche: Equity Ownership; Genentech Inc.: Employment, Equity Ownership. Dunbar:AbbVie Inc: Employment, Other: Stock/stock options. Zhou:AbbVie Inc: Employment, Other: Stock/stock options. Gressick:AbbVie Inc: Employment, Other: Stock/stock options. Ainsworth:AbbVie Inc: Employment, Other: Stock/stock options. Harb:AbbVie Inc: Employment, Other: Stock/stock options. Salem:AbbVie: Employment, Other: Stock/stock options. Hayslip:AbbVie Inc: Employment, Other: Stock/stock options. Swords:AbbVie Inc: Employment, Other: Stock/stock options. Garcia-Manero:Amphivena: Consultancy, Research Funding; Helsinn: Research Funding; Novartis: Research Funding; AbbVie: Research Funding; Celgene: Consultancy, Research Funding; Astex: Consultancy, Research Funding; Onconova: Research Funding; H3 Biomedicine: Research Funding; Merck: Research Funding. OffLabel Disclosure: Venetoclax is a BCL-2 inhibitor that is FDA-approved in some indications. This presentation will focus on venetoclax for treatment in myelodysplastic syndromes, which is not an approved indication.
- Published
- 2019
- Full Text
- View/download PDF
88. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)
- Author
-
Anthony S. Stein, Jing Gong, Giovanni Martinelli, Bin Wu, Peter Tan, Amer M. Zeidan, Stéphane de Botton, Eytan M. Stein, Thomas Winkler, Emmanuel Raffoux, Andre C. Schuh, Olga Frankfurt, Richard Stone, Paresh Vyas, Prapti A. Patel, Vickie Zhang, Hagop M. Kantarjian, Courtney D. DiNardo, Amir T. Fathi, and Du Hung Lam
- Subjects
Cancer Research ,IDH1 ,business.industry ,Azacitidine ,Mutant ,Myeloid leukemia ,Newly diagnosed ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Refractory ,030220 oncology & carcinogenesis ,Cancer research ,Medicine ,business ,030215 immunology ,medicine.drug - Abstract
7011 Background: IVO, a mutant IDH1 (mIDH1) inhibitor, is approved for the treatment of relapsed/refractory mIDH1 AML. We report results from an ongoing phase 1b study of patients (pts) with mIDH1 ND AML ineligible for intensive treatment who received combination IVO+AZA (NCT02677922). Methods: Pts received oral IVO 500 mg daily continuously and subcutaneous AZA 75 mg/m2 on D1–7 in 28-d cycles. ORR comprised CR + CRi/CRp + PR+ MLFS. CR with partial hematologic recovery (CRh) was defined as CR with ANC > 0.5×109/L and platelets > 50×109/L. Exploratory analysis included digital PCR assessment of m IDH1 allele frequency in bone marrow mononuclear cells (≤0.04% sensitivity). Results: As of 9Oct2018, 23 pts received IVO+AZA (11 male; median age 76 yrs [range 61–88]). Median duration of exposure was 11 mo (0.3–25.3); 12 pts remained on treatment at data cutoff. All-grade adverse events (AEs) regardless of cause in ≥30% pts were thrombocytopenia (65%), nausea (61%), diarrhea (57%), anemia (52%), constipation (52%), febrile neutropenia (39%), pyrexia (39%), vomiting (35%), fatigue (35%), hypokalemia (35%), dizziness (35%), insomnia (35%), and neutropenia (30%). AEs of special interest included ECG QT prolonged (26%), IDH differentiation syndrome (17%), and leukocytosis (13%). Grade 3/4 AEs in ≥10% pts were thrombocytopenia (61%), anemia (44%), febrile neutropenia (39%), neutropenia (26%), sepsis (22%), and ECG QT prolonged (13%). ORR was 78% (n = 18): CR 57%, CRi/CRp 13%, and MLFS 9%. CR+CRh rate was 70% (n = 16). Median time to response was 1.8 mo (0.7–3.8) and to CR 3.5 mo (0.8–6.0); median response duration not yet reached. m IDH1 clearance was seen in 10/16 pts (63%) with CR/CRh, including 9/13 (69%) with CR. Conclusions: IVO+AZA was well tolerated with a safety profile consistent with IVO or AZA monotherapy. All-grade cytopenia-related AEs were infrequent relative to other non-intensive therapies. CR and ORR rates exceeded those of AZA alone (Dombret et al., Blood 2015) and most responders achieved m IDH1 mutation clearance. Based on these findings, a phase 3 double-blind placebo-controlled study of IVO +AZA (AGILE, NCT03173248) is actively enrolling pts. Clinical trial information: NCT02677922.
- Published
- 2019
- Full Text
- View/download PDF
89. Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study
- Author
-
Rishad Khan, Misbah Salim, Peter Tanuseputro, Amy T. Hsu, Natalie Coburn, Julie Hallet, Robert Talarico, and Paul D. James
- Subjects
Pancreatic cancer ,end-of-life care ,population-based research ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We describe the association between initial treatment and end-of-life (EOL) outcomes among patients with pancreatic ductal adenocarcinoma (PDAC). Methods This population-based cohort study included patients with PDAC who died from April 2010–December 2017 in Ontario, Canada using administrative databases. We used multivariable models to explore the association between index cancer treatment (no cancer-directed therapy, radiation, chemotherapy, surgery alone, and surgery and chemotherapy), and primary (mortality, healthcare encounters and palliative care) and secondary outcomes (location of death, hospitalizations, and receipt of chemotherapy within the last 30 days of life). Results In our cohort (N = 9950), 56% received no cancer-directed therapy, 5% underwent radiation, 27% underwent chemotherapy, 7% underwent surgery alone, and 6% underwent surgery and chemotherapy. Compared to no cancer-directed therapy, radiation therapy (HR = 0.63), chemotherapy (HR = 0.43) surgery alone (HR = 0.32), and surgery and chemotherapy (HR = 0.23) were all associated with decreased mortality. Radiation (AMD = − 3.64), chemotherapy (AMD = -6.35), surgery alone (AMD = -6.91), and surgery and chemotherapy (AMD = -6.74) were all associated with fewer healthcare encounters per 30 days in the last 6 months of life. Chemotherapy (AMD = -1.57), surgery alone (AMD = -1.65), and surgery and chemotherapy (AMD = -1.67) were associated with fewer palliative care visits (all p-values for estimates above
- Published
- 2022
- Full Text
- View/download PDF
90. New or existing, does it matter?
- Author
-
Peter Tanner, Ramon Hingorani, and Carlos Lara
- Subjects
existing structures ,deterioration ,risk ,reliability ,robustness ,acceptance criteria ,assessment ,uncertainty ,updating ,probabilistic methods ,partial factors ,codes ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
Both when designing new and when evaluating existing structures, methods of analysis must be based on established engineering theory and practice. Also, the general principles of structural reliability regarding the treatment of uncertainties when verifying the established requirements apply to both, design and assessment. Taking further into account that new or existing civil engineering works are usually unique, either because they are prototypes or because they are exposed to specific conditions, from an engineering point of view, structural analysis and verification must be carried out, both in the design and in the assessment, under case-specific conditions according to the same principles. However, important differences exist between assessment and design, for example regarding the state of information and its updating through different types of information, the structural condition, reliability requirements, verification methods or decision options. Such differences, which are briefly summarized in the contribution, can often lead to a high level of conservatism when using design-oriented methods for assessment purposes. There is therefore a need to develop a generally recognized, coherent and harmonized set of rules for the assessment of existing structures. The CEN Technical Specification for assessment and retrofitting partially closes this gap, but only establishes principles on assessmentspecific reliability aspects. The consistent application of these generic assessment rules in practice requires further assumptions, or even case-specific developments. Practical applications are therefore of paramount importance in identifying relevant issues to consider in the future development of assessment methods and codes.
- Published
- 2022
- Full Text
- View/download PDF
91. Caring for older men and women: whose caregivers are more distressed? A population-based retrospective cohort study
- Author
-
Wenshan Li, Douglas G. Manuel, Sarina R. Isenberg, and Peter Tanuseputro
- Subjects
Caregiver distress ,Care-receiver’s gender ,Older men ,Older women ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background To our knowledge, no population-based studies have examined whether family or friend caregivers of men and women differ in their experience of distress over time. Thus, we aimed to describe, on a population-level and longitudinally, how older men and women care-receivers differed in their health and care needs, compare their caregivers’ distress trajectories, and identify factors that contribute to the observed differences. Methods This is a population-based, retrospective cohort study using routinely collected data. We examined longitudinally 485,407 community-dwelling Ontario residents, aged over 50 years, who have received at least one Residential Assessment Instrument-Home Care (RAI-HC) assessment between April 2008 and June 2015. Descriptive analyses were performed on the demographic characteristics, health profiles, and care needs of men and women. We also compared their caregivers’ baseline and one-year change in distress status. Logistic regressions were performed to examine if the effect of gender on caregiver distress is reduced after controlling for care-receiver’s health and functional status as well as their caregiver’s kinship and co-residence status. Results Men (39.5% of our cohort) were frailer, required more care, were mostly cared for by their spouses (52%), and mostly lived with their caregiver (66%). In contrast, women (60.5%) were more likely cared for by their child/child-in-law (60%), less likely to live with caregivers (47%), and received less care. Caregivers of men were more likely to be distressed at baseline (27.7% versus 20.4% of women caregivers) and remain distressed (74.6% versus 69.5%) or become distressed (19.3% versus 14.3%) throughout the year. In logistic regression modelling, the effect of care-receiver’s gender on caregiver distress is reduced from an unadjusted odds ratio of 1.49 (95% CI: 1.47–1.51) to 1.17 (95% CI: 1.15–1.19) when care-receiver’s health and caregiving factors are controlled for. Conclusion Older men and women differed in health and care needs. Caregivers, especially those caring for men, were often distressed and remained so through time. These results highlight the need for policies that account for the differential care needs and caregiver profiles of men and women in order to offer targetted and appropriate support.
- Published
- 2022
- Full Text
- View/download PDF
92. Exploring Primary Care Physicians’ Experiences of Language and Cultural Discordant Care for Linguistic Minority Patients at the End-of-Life: A Study Protocol
- Author
-
Seung Heyck Lee, Maya Gibb, Sathya Karunananthan, Margaret Cody, Peter Tanuseputro, Sharon Johnston, Claire Kendall, Daniel Bedard, Stéphanie Collin, and Krystal Kehoe MacLeod
- Subjects
Social sciences (General) ,H1-99 - Abstract
Health disparities exist across different linguistic groups. Language barriers in primary care can negatively affect access to healthcare services and the quality and safety of care at the end-of-life. This study will take a novel, in-depth look at the experience of language- and/or cultural-discordant care for adults from linguistic minority groups through the eyes of primary care physicians providing palliative and/or end-of-life care. Language and cultural discordance means that the physician and patient do not speak the same language or are not from the same cultural background. Qualitative data from primary care physicians ( n = 12–24) providing language-discordant end-of-life care to Francophone and/or Allophone older adults across different care models and diverse geographies in Ontario will be collected through semi-structured interviews. Reflexive thematic analysis will be used to report themes within the data and consider the influence of the social locations of the researcher and research participants, geographic considerations impacting service provision, and barriers imposed by differing primary care funding structures on the provision of palliative and end-of-life care for linguistic and cultural minority groups in Ontario. Findings from this study will identify the interconnections among language and cultural discordance, care model, geographic region, and physician perceptions of their combined effects on access to, and quality of, palliative and end-of-life care. This evidence will be key to informing clinical practice guidelines and mobilizing change to improve primary care access and quality for adults at the end-of-life from linguistic and cultural minority populations across Ontario.
- Published
- 2023
- Full Text
- View/download PDF
93. Comorbidities, symptoms and end-of-life medication use in hospitalised decedents before and during the COVID-19 pandemic: a retrospective regional cohort study in Ottawa, Canada
- Author
-
Shirley H Bush, Monisha Kabir, Peter Lawlor, James Downar, Brandi Vanderspank-Wright, Sarina Isenberg, Peter Tanuseputro, Akshai Iyengar, Claire Dyason, Julie Lapenskie, Colleen Webber, Henrique Parsons, Samantha Rose Adeli, Ella Besserer, Leila Cohen, Valérie Gratton, Rebekah Murphy, Grace Warmels, Adrianna Bruni, Chelsea Noel, Brandon Heidinger, Koby Anderson, Kyle Arsenault-Mehta, Krista Wooller, Daniel Bedard, Paula Enright, Isabelle Desjardins, and Khadija Bhimji
- Subjects
Medicine - Abstract
Objective To compare comorbidities, symptoms and end-of-life (EoL) palliative medication (antisecretories, opioids, antipsychotics and sedatives) use among decedents before and during the COVID-19 pandemic.Design In a retrospective cohort study, decedent records in three acute care hospitals were abstracted, generating a prepandemic (November 2019–February 2020) group (pre-COVID) and two intrapandemic (March–August 2020, wave 1) groups, one without (COVID-ve) and one with COVID-19 infection (COVID+ve). Control group decedents were matched 2:1 on age, sex and care service (medicine/intensive care unit (ICU)) with COVID+ve decedents.Setting Three regional acute care teaching hospitals in Ottawa, CanadaParticipants Decedents (N=425): COVID+ve (n=85), COVID-ve (n=170) and pre-COVID (n=170).Main outcome measures Data were abstracted regarding demographics, admission comorbidities and symptoms, and EoL medication use; opioid doses were standardised to parenteral morphine equivalent daily dose (MEDD), and the predictors of upper quartile MEDD in the last 24 hours of life were examined in multivariable logistic regression with adjusted ORs (aORs) and 95% CIs.Results The prevalence of dementia (41% vs 28% and 26%, p=0.03), breathlessness (63.5% vs 42% and 47%, p
- Published
- 2023
- Full Text
- View/download PDF
94. Higher Education Institutions and ASEAN: Current Trends and Implications for Future Innovation and Change
- Author
-
Peter Tan Keo and Alexander Jun
- Subjects
Economic growth ,Higher education ,Order (exchange) ,business.industry ,Political science ,Regionalism (international relations) ,Centrality ,business ,Southeast asian ,Southeast asia ,Intellectual capital - Abstract
Regionalism and fragmentation of higher education institutions (HEIs) in Southeast Asia (SEA) is potentially disruptive to the Association of Southeast Asian Nations (ASEAN) Centrality. ASEAN often relies on the export of Southeast Asian students to countries outside of ASEAN, and students are exchanged to acquire skills that can be gained in the region. In this chapter the authors examine how, and to what extent, an intra-regional organization such as the Southeast Asian Ministers of Education Organization (SEAMEO) can lead to establish the foundation for a strong, vibrant culture of HEIs in SEA. In this chapter the authors submit that high-demand skills in fields such as science and technology ought to be a long-term vision of how HEIs can become leaders of research and innovation. They further suggest that academic leaders and policy makers serving universities should ensure that research is a core mission of their HEIs and that national and regional (ASEAN and SEAMEO) funding, coordination, and preparation of faculty and students ought to be strengthened in order to ensure that a rigorous culture of research is prioritized.
- Published
- 2016
- Full Text
- View/download PDF
95. Mapping Cropping Practices Using MODIS Time Series: Harnessing the Data Explosion
- Author
-
Peter Tan, Adam Lewis, Leo Lymburner, and Medhavy Thankappan
- Subjects
Earth observation ,Geography ,Series (mathematics) ,Geography, Planning and Development ,Earth and Planetary Sciences (miscellaneous) ,Wavelet transform ,Statistical model ,Land cover ,Moderate-resolution imaging spectroradiometer ,Time series ,Cropping ,Remote sensing - Abstract
The MODIS (Moderate Resolution Imaging Spectroradiometer) 250m EVI dataset provides a valuable ongoing means of characterising and monitoring changes in land use and resource condition. However the multiple factors that influence a time series of greenness data make the data difficult to analyse and interpret. Without prior knowledge, underlying models for time series in a given remote sensing image are often heterogeneous. So while conventional time series analysis methods such as wavelet transform and Fourier analysis may work well for part of the image, these models are either invalid or must be substantially re-parameterised for other parts of the image. To overcome these challenges we propose a new approach to distil information from earth observation time series data. The characteristics of a remote sensing time series are represented by a set of statistics (which we call coefficients) selected to correspond to the dynamics of a natural system. To ensure the coefficients are robust and generic, statistics are calculated independently by applying statistical models with less complexity on shorter segments within the time series. An International Standards Organization (ISO) Land Cover classification (Jansen 2000) was generated for cropping regions in the Gwydir and Namoi catchments, in Australia. Areas identified in the classification as irrigated and rain fed cropping were analysed using a tailored time series analysis tool. The crop analysis tool identifies time series features such as the number and duration of fallow periods, crop timing, presence/absence of a crop during a year for a specific growing season. This information is combined with paddock boundaries derived from Landsat imagery to provide detailed year-by-year insight into cropping practices in the Gwydir and Namoi catchments.
- Published
- 2011
- Full Text
- View/download PDF
96. An Evaluation of the Use of Atmospheric and BRDF Correction to Standardize Landsat Data
- Author
-
Peter Tan, Shanti Reddy, David L.B. Jupp, Norman Mueller, Fuqin Li, Anisul Islam, and Leo Lymburner
- Subjects
Atmospheric Science ,Spectroradiometer ,Atmospheric radiative transfer codes ,Meteorology ,MODTRAN ,Atmospheric correction ,Radiometry ,Moderate-resolution imaging spectroradiometer ,Bidirectional reflectance distribution function ,Atmospheric model ,Computers in Earth Sciences ,Remote sensing - Abstract
Normalizing for atmospheric and land surface bidirectional reflectance distribution function (BRDF) effects is essential in satellite data processing. It is important both for a single scene when the combination of land covers, sun, and view angles create anisotropy and for multiple scenes in which the sun angle changes. As a consequence, it is important for inter-sensor calibration and comparison. Procedures based on physics-based models have been applied successfully with the Moderate Resolution Imaging Spectroradiometer (MODIS) data. For Landsat and other higher resolution data, similar options exist. However, the estimation of BRDF models using internal fitting is not available due to the smaller variation of view and solar angles and infrequent revisits. In this paper, we explore the potential for developing operational procedures to correct Landsat data using coupled physics-based atmospheric and BRDF models. The process was realized using BRDF shape functions derived from MODIS with the MODTRAN 4 radiative transfer model. The atmospheric and BRDF correction algorithm was tested for reflectance factor estimation using Landsat data for two sites with different land covers in Australia. The Landsat reflectance values had a good agreement with ground based spectroradiometer measurements. In addition, overlapping images from adjacent paths in Queensland, Australia, were also used to validate the BRDF correction. The results clearly show that the algorithm can remove most of the BRDF effect without empirical adjustment. The comparison between normalized Landsat and MODIS reflectance factor also shows a good relationship, indicating that cross calibration between the two sensors is achievable.
- Published
- 2010
- Full Text
- View/download PDF
97. Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD)
- Author
-
Mohit Madken, Ranjeeta Mallick, Emily Rhodes, Roshanak Mahdavi, Anan Bader Eddeen, Gregory L. Hundemer, Dearbhla M. Kelly, Angelo Karaboyas, Bruce Robinson, Brian Bieber, Amber O. Molnar, Sunil V. Badve, Peter Tanuseputro, Gregory Knoll, and Manish M. Sood
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Background: Individuals with kidney disease are at a high risk of bleeding and as such tools that identify those at highest risk may aid mitigation strategies. Objective: We set out to develop and validate a prediction equation (BLEED-HD) to identify patients on maintenance hemodialysis at high risk of bleeding. Design: International prospective cohort study (development); retrospective cohort study (validation). Settings: Development: 15 countries (Dialysis Outcomes and Practice Patterns Study [DOPPS] phase 2-6 from 2002 to 2018); Validation: Ontario, Canada. Patients: Development: 53 147 patients; Validation: 19 318 patients. Measurements: Hospitalization for a bleeding event. Methods: Cox proportional hazards models. Results: Among the DOPPS cohort (mean age, 63.7 years; female, 39.7%), a bleeding event occurred in 2773 patients (5.2%, event rate 32 per 1000 person-years), with a median follow-up of 1.6 (interquartile range [IQR], 0.9-2.1) years. BLEED-HD included 6 variables: age, sex, country, previous gastrointestinal bleeding, prosthetic heart valve, and vitamin K antagonist use. The observed 3-year probability of bleeding by deciles of risk ranged from 2.2% to 10.8%. Model discrimination was low to moderate (c-statistic = 0.65) with excellent calibration (Brier score range = 0.036-0.095). Discrimination and calibration of BLEED-HD were similar in an external validation of 19 318 patients from Ontario, Canada. Compared to existing bleeding scores, BLEED-HD demonstrated better discrimination and calibration (c-statistic: HEMORRHAGE = 0.59, HAS-BLED = 0.59, and ATRIA = 0.57, c-stat difference, net reclassification index [NRI], and integrated discrimination index [IDI] all P value
- Published
- 2023
- Full Text
- View/download PDF
98. Characteristics and Outcomes of ICU Patients Without COVID-19 Infection—Pandemic Versus Nonpandemic Times: A Population-Based Cohort Study
- Author
-
Cameron W. Leafloor, MD, Haris Imsirovic, MSc, Danial Qureshi, MSc, PhD(c), Christina Milani, MSc, Kwadjo Nyarko, Sarah E. Dickson, Laura Thompson, PhD, Peter Tanuseputro, MD, MHSc, and Kwadwo Kyeremanteng, MD, MHA
- Subjects
Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
IMPORTANCE:. Outcomes for critically ill COVID-19 are well described; however, the impact of the pandemic on critically ill patients without COVID-19 infection is less clear. OBJECTIVES:. To demonstrate the characteristics and outcomes of non-COVID patients admitted to an ICU during the pandemic, compared with the previous year. DESIGN:. A population-based study conducted using linked health administrative data comparing a cohort from March 1, 2020, to June 30, 2020 (pandemic) to a cohort from March 1, 2019, to June 30, 2019 (nonpandemic). SETTING AND PARTICIPANTS:. Adult patients (18 yr old) admitted to an ICU in Ontario, Canada, without a diagnosis of COVID-19 during the pandemic and nonpandemic periods. MAIN OUTCOMES AND MEASURES:. The primary outcome was all-cause in-hospital mortality. Secondary outcomes included hospital and ICU length of stay, discharge disposition, and receipt of resource intensive procedures (e.g., extracorporeal membrane oxygenation, mechanical ventilation, renal replacement therapy, bronchoscopy, feeding tube insertion, and cardiac device insertion). We identified 32,486 patients in the pandemic cohort and 41,128 in the nonpandemic cohort. Age, sex, and markers of disease severity were similar. Fewer patients in the pandemic cohort were from long-term care facilities and had fewer cardiovascular comorbidities. There was an increase in all-cause in-hospital mortality among the pandemic cohort (13.5% vs 12.5%; p < 0.001) representing a relative increase of 7.9% (adjusted odds ratio, 1.10; 95% CI, 1.05–1.56). Patients in the pandemic cohort admitted with chronic obstructive pulmonary disease exacerbation had an increase in all-cause mortality (17.0% vs 13.2%; p = 0.013), a relative increase of 29%. Mortality among recent immigrants was higher in the pandemic cohort compared with the nonpandemic cohort (13.0% vs 11.4%; p = 0.038), a relative increase of 14%. Length of stay and receipt of intensive procedures were similar. CONCLUSIONS AND RELEVANCE:. We found a modest increase in mortality among non-COVID ICU patients during the pandemic compared with a nonpandemic cohort. Future pandemic responses should consider the impact of the pandemic on all patients to preserve quality of care.
- Published
- 2023
- Full Text
- View/download PDF
99. Physician benzodiazepine self-use prior to and during the COVID-19 pandemic in Ontario, Canada: a population-level cohort study
- Author
-
Peter Tanuseputro, Tetyana Kendzerska, Claire E Kendall, Michael Pugliese, Daniel Myran, Christina Milani, Jennifer M Hensel, and Manish Sood
- Subjects
Medicine - Abstract
Objectives The aim of this study was to investigate physician benzodiazepine (BZD) self-use pre-COVID-19 pandemic and to examine changes in BZD self-use during the first year of the pandemic.Design Population-based retrospective cohort study using linked routinely collected administrative health data comparing the first year of the pandemic to the period before the pandemic.Setting Province of Ontario, Canada between March 2016 and March 2021.Participants Intervention Onset of the COVID-19 pandemic in March 2020.Outcomes measures The primary outcome measure was the receipt of one or more prescriptions for BZD, which was captured via the Narcotics Monitoring System.Results In a cohort of 30 798 physicians (mean age 42, 47.8% women), we found that during the year before the pandemic, 4.4% of physicians had 1 or more BZD prescriptions. Older physicians (6.8% aged 50+ years), female physicians (5.1%) and physicians with a prior mental health (MH) diagnosis (12.4%) were more likely than younger (3.7% aged
- Published
- 2023
- Full Text
- View/download PDF
100. Mental health and addiction health service use by physicians compared to non-physicians before and during the COVID-19 pandemic: A population-based cohort study in Ontario, Canada.
- Author
-
Daniel T Myran, Rhiannon Roberts, Eric McArthur, Nivethika Jeyakumar, Jennifer M Hensel, Claire Kendall, Caroline Gerin-Lajoie, Taylor McFadden, Christopher Simon, Amit X Garg, Manish M Sood, and Peter Tanuseputro
- Subjects
Medicine - Abstract
BackgroundThe Coronavirus Disease 2019 (COVID-19) pandemic has exacerbated mental health challenges among physicians and non-physicians. However, it is unclear if the worsening mental health among physicians is due to specific occupational stressors, reflective of general societal stressors during the pandemic, or a combination. We evaluated the difference in mental health and addictions health service use between physicians and non-physicians, before and during the COVID-19 pandemic.Methods and findingsWe conducted a population-based cohort study in Ontario, Canada between March 11, 2017 and August 11, 2021 using data collected from Ontario's universal health system. Physicians were identified using registrations with the College of Physicians and Surgeons of Ontario between 1990 and 2020. Participants included 41,814 physicians and 12,054,070 non-physicians. We compared the first 18 months of the COVID-19 pandemic (March 11, 2020 to August 11, 2021) to the period before COVID-19 pandemic (March 11, 2017 to February 11, 2020). The primary outcome was mental health and addiction outpatient visits overall and subdivided into virtual versus in-person, psychiatrists versus family medicine and general practice clinicians. We used generalized estimating equations for the analyses. Pre-pandemic, after adjustment for age and sex, physicians had higher rates of psychiatry visits (aIRR 3.91 95% CI 3.55 to 4.30) and lower rates of family medicine visits (aIRR 0.62 95% CI 0.58 to 0.66) compared to non-physicians. During the first 18 months of the COVID-19 pandemic, the rate of outpatient mental health and addiction (MHA) visits increased by 23.2% in physicians (888.4 pre versus 1,094.7 during per 1,000 person-years, aIRR 1.39 95% CI 1.28 to 1.51) and 9.8% in non-physicians (615.5 pre versus 675.9 during per 1,000 person-years, aIRR 1.12 95% CI 1.09 to 1.14). Outpatient MHA and virtual care visits increased more among physicians than non-physicians during the first 18 months of the pandemic. Limitations include residual confounding between physician and non-physicians and challenges differentiating whether observed increases in MHA visits during the pandemic are due to stressors or changes in health care access.ConclusionsThe first 18 months of the COVID-19 pandemic was associated with a larger increase in outpatient MHA visits in physicians than non-physicians. These findings suggest physicians may have had larger negative mental health during COVID-19 than the general population and highlight the need for increased access to mental health services and system level changes to promote physician wellness.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.